Predicted protein targets (top 8)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | BMI1 | P35226 | 8/20 | 0.54 |
| ▸ | PIK3CB | P42338 | 10/20 | 0.44 |
| ▸ | PIK3CD | O00329 | 6/20 | 0.44 |
| ▸ | PIK3CA | P42336 | 5/20 | 0.44 |
| ▸ | PIK3CG | P48736 | 5/20 | 0.44 |
| ▸ | PIK3R1 | P27986 | 2/20 | 0.44 |
| ▸ | PIK3C2B | O00750 | 1/20 | 0.44 |
| ▸ | MTOR | P42345 | 1/20 | 0.44 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL15747673 | 0.92 | BMI1 (0.55) | BMI1PIK3CBPIK3CDPIK3CAPIK3CG | |
| SCHEMBL15741358 | 0.87 | BMI1 (0.70) | BMI1PIK3CBPIK3CDPIK3CAPIK3CG | |
| SCHEMBL17234730 | 0.87 | PIK3CB (0.43) | BMI1PIK3CBPIK3CDPIK3CAPIK3CG | |
| SCHEMBL15747469 | 0.84 | BMI1 (0.55) | BMI1PIK3CBPIK3CDPIK3CAPIK3CG | |
| SCHEMBL15741401 | 0.84 | BMI1 (0.71) | BMI1PIK3CBPIK3CDPIK3CAPIK3CG | |
| SCHEMBL15742179 | 0.83 | BMI1 (0.71) | BMI1 | |
| SCHEMBL16748513 | 0.82 | BMI1 (0.50) | BMI1PIK3CBPIK3CDPIK3CAPIK3CG | |
| SCHEMBL17223108 | 0.81 | BMI1 (0.52) | BMI1PIK3CBPIK3CDPIK3CAPIK3CG | |
| SCHEMBL17223122 | 0.81 | BMI1 (0.57) | BMI1 | |
| SCHEMBL16540632 | 0.81 | BMI1 (0.54) | BMI1PIK3CBPIK3CDPIK3CAPIK3CG |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 15 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-11180483-B2 | Substituted reverse pyrimidine Bmi-1 inhibitors | PTC THERAPEUTICS, INC. (US) | 2021-11-23 | — | — | US | claimed |
| EP-2922828-B1 | 4,6-DIAMINO-PYRIMIDINE DERIVATIVES AS BMI-1 INHIBITORS FOR TREATING CANCER | PTC THERAPEUTICS INC (US) | 2020-07-08 | — | — | EP | claimed |
| US-10428050-B2 | Substituted reverse pyrimidine Bmi-1 inhibitors | PTC THERAPEUTICS, INC. (US) | 2019-10-01 | — | — | US | claimed |
| US-20150315182-A1 | SUBSTITUTED REVERSE PYRIMIDINE BMI-1 INHIBITORS | PTC THERAPEUTICS, INC. | 2015-11-05 | — | — | US | claimed |
| US-20220064150-A1 | SUBSTITUTED REVERSE PYRIMIDINE BMI-1 INHIBITORS | PTC THERAPEUTICS INC (US) | 2022-03-03 | — | — | US | disclosed |
| US-20220064150-A1 | SUBSTITUTED REVERSE PYRIMIDINE BMI-1 INHIBITORS | PTC THERAPEUTICS INC (US) | 2022-03-03 | — | — | US | disclosed |
| US-11180483-B2 | Substituted reverse pyrimidine Bmi-1 inhibitors | PTC THERAPEUTICS, INC. (US) | 2021-11-23 | — | — | US | disclosed |
| US-11180483-B2 | Substituted reverse pyrimidine Bmi-1 inhibitors | PTC THERAPEUTICS, INC. (US) | 2021-11-23 | — | — | US | disclosed |
| EP-2922828-B1 | 4,6-DIAMINO-PYRIMIDINE DERIVATIVES AS BMI-1 INHIBITORS FOR TREATING CANCER | PTC THERAPEUTICS INC (US) | 2020-07-08 | — | — | EP | disclosed |
| EP-2922828-B1 | 4,6-DIAMINO-PYRIMIDINE DERIVATIVES AS BMI-1 INHIBITORS FOR TREATING CANCER | PTC THERAPEUTICS INC (US) | 2020-07-08 | — | — | EP | disclosed |
| US-10428050-B2 | Substituted reverse pyrimidine Bmi-1 inhibitors | PTC THERAPEUTICS, INC. (US) | 2019-10-01 | — | — | US | disclosed |
| US-10428050-B2 | Substituted reverse pyrimidine Bmi-1 inhibitors | PTC THERAPEUTICS, INC. (US) | 2019-10-01 | — | — | US | disclosed |
| US-20150315182-A1 | SUBSTITUTED REVERSE PYRIMIDINE BMI-1 INHIBITORS | PTC THERAPEUTICS, INC. | 2015-11-05 | — | — | US | disclosed |
| US-20150315182-A1 | SUBSTITUTED REVERSE PYRIMIDINE BMI-1 INHIBITORS | PTC THERAPEUTICS, INC. | 2015-11-05 | — | — | US | disclosed |
| WO-2014081906-A2 | SUBSTITUTED REVERSE PYRIMIDINE BMI-1 INHIBITORS | PTC THERAPEUTICS, INC. (US) | 2014-05-30 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (4 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-11180483-B2 | Substituted reverse pyrimidine Bmi-1 inhibitors | BMI1, BRPF3, BAZ2A | BMI1 1/4885PIK3CB 1755/4885PIK3CD 2320/4885 |
| US-20150315182-A1 | SUBSTITUTED REVERSE PYRIMIDINE BMI-1 INHIBITORS | BMI1, BRPF3, BAZ2A | BMI1 1/4885PIK3CB 1755/4885PIK3CD 2320/4885 |
| US-10428050-B2 | Substituted reverse pyrimidine Bmi-1 inhibitors | BMI1, BRPF3, BAZ2A | BMI1 1/4885PIK3CB 1755/4885PIK3CD 2320/4885 |
| US-20220064150-A1 | SUBSTITUTED REVERSE PYRIMIDINE BMI-1 INHIBITORS | BMI1, BRPF3, BAZ2A | BMI1 1/4885PIK3CB 1755/4885PIK3CD 2320/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.